期刊文献+

2-三氟甲基喹唑啉衍生物的合成及抗肿瘤活性研究 被引量:3

Synthesis and Antitumor Activity of 2-Trifluoromethylquinazoline Derivatives
下载PDF
导出
摘要 设计合成新型2-三氟甲基喹唑啉类化合物,以期发现高效低毒的抗肿瘤活性目标分子。以2-氨基-5-硝基苯甲酸为原料,经过三氟乙酰化、环化、氯代及偶联等反应,设计合成10个2-三氟甲基喹唑啉类化合物,并通过^(1)HNMR、^(13)CNMR、^(19)FNMR进行结构确证。采用四氮唑蓝(MTT)法评价目标化合物的体外抗肿瘤活性,合成的大部分目标化合物对前列腺癌细胞(PC3、LNCaP)、人慢性髓系白血病细胞(K562)这3种癌细胞都有一定的抑制作用,其中,N-(4-甲氧基苯基)-N-甲基-2-(三氟甲基)喹唑啉-4,6-二胺的IC;分别为25.2(PC3)、515.7(LNCaP)、248.7 nmol/L(K562),该结果为2-三氟甲基喹唑啉类化合物在抗肿瘤方面的进一步研究提供参考。 To discover high efficiency and low toxicity target compounds,ten novel derivatives of 2-trifluoromethylquinazoline were designed and synthesized from 2-amino-5-nitrobenzoic acid by trifluoacylation,cyclization,chlorination and coupling reaction.The structures of all target compounds were confirmed by ^(1)HNMR,^(13)CNMR,^(19)FNMR and their anti-tumor activities in vitro were demonstrated by MTT assays.Most of them had a certain inhibitory activity against prostate cancer cell lines(PC3,LNCaP),human chronic myeloid leukemia cell line(K562).The half maximal inhibitory concentration values of compound N-(4-Methoxyphenyl)-N-methyl-2-(trifluoromethyl)quinazoline-4,6-diamine against PC3,LNCaP and K562 cell lines were 25.2,515.7 and 248.7 nmol/L,respectively.The results could provide reference for further investigation of the derivatives of 2-trifluoromethylquinazoline as antitumor agents.
作者 吴辉 余佳 余刚 曾晓萍 徐广灿 孟雪玲 徐必学 WU Hui;YU Jia;YU Gang;ZENG Xiao-ping;XU Guang-can;MENG Xue-ling;XU Bi-xue(State Key Laboratory of Functions and Applications of Medicinal Plants,Guizhou Medical University,Guiyang 550014,China;School of Pharmaceutical Sciences,Guizhou Medical University,Guiyang 550025,China;Key Laboratory of Chemistry for Natural Products of Guizhou and Chinese Academy of Sciences,Guiyang 550014,China)
出处 《化学试剂》 CAS 北大核心 2022年第5期668-673,共6页 Chemical Reagents
基金 贵州省高层次创新型人才培养计划项目(黔科云平台人才[2016]5678) 黔科合基础-ZK[2021]一般070。
关键词 喹唑啉 三氟甲基 合成 MTT法 抗肿瘤活性 quinazoline trifluoromethyl synthesis MTT assays antitumor activity
  • 相关文献

参考文献2

二级参考文献25

  • 1ZHANG J,YANG P L,GRAY N S. Targeting cancer with small molecule kinase inhibitors [ J ]. Nat. Rev. , 2009,9 (1) :28-39.
  • 2中华人民共和国卫生部统计信息中心[M].中国卫生统计年鉴2012卷,2013.
  • 3MANNING G, WHYTE D B, MARTINEZ R, et al. The protein kinase complement of the human genome[ J]. Sci- ence, 2002,298 ( 5 600 ) : 1 912-1 934.
  • 4PARANG K,SUN G. Design strategies for protein kinase inhibitors[ J ]. Curr. Opin. Drug. Disc. , 2004,7 (5) :617- 629.
  • 5ZHONG H,BOWEN J P. Recent advances in small mole- cule inhibitors of VEGFR and EGFR signaling pathways [J]. Curr. Top. Med. Chem. ,2011,11 (12): 1 571- 1 590.
  • 6TRAXLER P. Tyrosine kinase inhibitors in cancer treat- ment [ J ]. Exp. Opin. Ther. Pat., 1998,8 ( 12 ) : 1 599- 1 625.
  • 7RUSNAK D W,AFFLECK K, COCKERILL S G,et al. The characterization of novel, dual ErbB-2/EGFR, tyro- sine kinase inhibitors: potential therapy for cancer [ J ]. Can. Res. , 2001,61 ( 19 ) : 7 196-7 203.
  • 8MOYER J D,BARBACCI E G,IWATA K K,et al. Induc- tion of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine ki- nase[ J]. Can. Res., 1997,57(21 ) :4 838-4 848.
  • 9MOY B, KIRKPATRICK P, KAR S. Lapatinib [ J ]. Nat. Rev. ,2007,6(6) :431-432.
  • 10LACKEY K E. Lessons from the drug discovery of lapa- tinib, a dual ErbB1/2. tyrosine kinase inhibitor [ J ]. Curr. Top. Med. Chem. ,2006,6($) :435-460.

共引文献5

同被引文献27

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部